Blood grouping by molecular genetics


  • 2A-E1.3

Geoff Daniels, PhD FRCPath, Bristol Institute for Transfusion Sciences, NHS Blood and Transplant, North Bristol Park, 500 Northway, Filton, Bristol, BS34 7QH, UK


It is possible to predict most clinically important blood group phenotypes from genomic DNA. Clinical applications include the following: determining foetal blood group to assess risk of haemolytic disease of the foetus and newborn or whether the pregnant woman requires antenatal anti-D prophylaxis; testing multiply transfused and autoimmune haemolytic anaemia patients; defining D variants; detecting donors with very weak D antigens; testing donors and patients when appropriate antisera are not available; RHD zygosity testing; zygosity testing of panel cells; assisting in solving difficult serological problems; and, with the use of high-throughput technologies, extended blood grouping of donors. Over the last 7 years, ISBT Workshops have provided external quality assurance. Future technologies may involve matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and massively parallel (next generation) sequencing.